Grifols, S.A. (GRFS)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
15.97-0.16 (-0.99%)
At close: 4:00 PM EDT
People also watch:
SHPGIRWDAKRXPCRXEPZM
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.00
Prev Close16.13
Bid15.78 x 700
Ask15.94 x 600
Day's Range15.97 - 16.10
52wk Range14.07 - 18.04
1y Target EstN/A
Market Cap21.82B
P/E Ratio (ttm)36.42
Beta1.01
Volume381,251
Avg Vol (3m)770,042
Dividend & Yield0.52 (3.23%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • TheStreet.com19 days ago

    5 Big Dividend Stocks Billionaire John Paulson Loves

    Here's a closer look at five dividend stocks that Paulson & Co. owned in the most recently reported quarter.

  • PR Newswire22 days ago

    Grifols Opens Diagnostic Training Center in Dubai

    BARCELONA, Spain, Sept. 5, 2016 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS),  a global healthcare company with more than 75-year legacy of improving people's health and well-being, today celebrated the opening of its new training center in Dubai. Created to support the company's growing Diagnostic business, the center will offer single and multi-day training courses for laboratory technicians, engineers, and specialists working with the company's broad portfolio of Transfusion Medicine and Clinical Diagnostic instruments, assays, and software. "Locating this new center in Dubai, a city focused on being a healthcare center of excellence, allows us to more closely partner with customers throughout the Middle East and Africa working to provide excellent care to patients," said Carsten Schroeder, president of the Grifols Diagnostic Division.

  • New Zika Screening Rule Could Boost Hologic Sales Growth
    Investor's Business Dailylast month

    New Zika Screening Rule Could Boost Hologic Sales Growth

    The advisory that all U.S. blood centers screen for Zika is good news for Hologic's Procleix test.